CANFNYSEPharmaceutical PreparationsFiscal year ends December 31

Can-Fite BioPharma Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$1.89+0.13 (+7.39%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Can-Fite BioPharma Ltd. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	0.41	0.67	0.74	0.81	0.85	0.76	2.03	3.82	0.79	0.17	0.16
Research & Development	6.69	5.76	5.98	7.76	9.85	12	11	6.08	5.11	6.12	3.90
Selling, General & Admin	–	–	–	0.26	0.47	0.32	3.06	3.16	2.87	2.73	2.74
General & Administrative	3.66	3.05	2.96	3.14	3.85	2.95	3.06	3.16	2.87	2.73	2.74
Operating Expenses	10	8.80	8.94	11	–	–	–	–	–	–	–
Operating Income	-9.95	-8.13	-8.20	-10	-13	-14	-12	-5.41	-7.19	-8.68	-6.48
Interest Expense	0.28	0.29	0.51	-0.22	–	–	0.69	1.20	0.62	0.06	-0.13
Interest & Investment Income	–	–	–	–	–	–	3.11	0.05	0.63	0.37	-0.11
Other Non-Operating Income	0.12	0.25	0.56	-0.08	0.23	-0.30	-0.62	-1.15	1.60	–	–
Asset Impairment Charges	–	–	–	–	–	0	0	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	0.16	0.01	–	–	–	–	–
Pretax Income	-9.83	-7.88	-7.63	-10	-13	-14	-13	-6.57	-4.81	-8.36	-6.50
Income Tax Expense	–	–	–	–	–	–	–	0.00	0.03	0.03	0.01
Income from Continuing Operations	–	–	–	–	–	–	–	-1.15	0.01	0.32	-0.03
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	-13	-6.57	-4.84	-8.39	-6.51
Minority Interest in Earnings	–	–	–	–	–	–	–	–	-0.09	0.14	0.27
Net Income	-9.83	-7.88	-7.63	-10	-13	-14	-13	-6.57	-4.84	8.26	6.24
EPS (Basic)(per share)	-5.97	-10.86	-17.92	-30.00	-90.00	-120.00	-420.00	-510.00	-420.00	900.00	810.00
EPS (Diluted)(per share)	-5.97	-10.86	-17.92	-30.00	-90.00	-120.00	-420.00	-510.00	-420.00	900.00	810.00
Shares Outstanding (Basic, Weighted)(shares)	1.65	0.73	0.43	0.27	0.18	0.12	0.03	0.01	0.01	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	1.65	0.73	0.43	0.27	0.18	0.12	0.03	0.01	0.01	0.01	0.00
EBITDA	-9.93	-8.12	-8.18	-10	-13	-14	-12	-5.40	–	–	–
Net Interest Income	–	–	–	-0.08	0.23	-0.30	-0.62	-1.15	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -2456.8%
Net margin: -2426.7%
Return on equity, FY2025: -178.2%

Financial strength

Current ratio: 3.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 134.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –